The efficacy of postoperative radiotherapy in resected pⅢA-N2 EGFR mutant and wild-type lung adenocarcinoma
Yue Zeng,
Xing-Xiang Pu,
Feng-Jiao He,
Chun-Hong Hu,
Hong Zhu,
Yan Huang,
Yu-Rong Peng,
Ji-An Zou,
Jun-Qi Liu,
Sheng-Hao Shi,
Yue-Fei Liu,
Fang Ma,
Chao Deng,
Zhen-Hua Qiu,
Yan-Long Li,
Ying-Zhe Zhang,
Kun Huang,
Xian-Ling Liu,
Fang Wu
Affiliations
Yue Zeng
Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China
Xing-Xiang Pu
Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan 410013, China
Feng-Jiao He
Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China; Hunan Academy of Traditional Chinese Medicine Affiliated Hospital, Changsha, Hunan 410006, China
Chun-Hong Hu
Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China; Hunan Cancer Mega-Data Intelligent Application and Engineering Research Centre, Changsha, Hunan 410011, China
Hong Zhu
Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China
Yan Huang
Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China
Yu-Rong Peng
Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China
Ji-An Zou
Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China
Jun-Qi Liu
Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China
Sheng-Hao Shi
Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China
Yue-Fei Liu
Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China
Fang Ma
Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China
Chao Deng
Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China
Zhen-Hua Qiu
Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China
Yan-Long Li
Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China
Ying-Zhe Zhang
Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China
Kun Huang
Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China
Xian-Ling Liu
Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China
Fang Wu
Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China; Hunan Cancer Mega-Data Intelligent Application and Engineering Research Centre, Changsha, Hunan 410011, China; Hunan Key Laboratory of Tumor Models and Individualized Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China; Hunan Key Laboratory of Early Diagnosis and Precision Therapy in Lung Cancer, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China; FuRong Laboratory, Changsha, Hunan 410078, China; Corresponding author
Summary: The resected pⅢA-N2 non-small-cell lung cancer (NSCLC) patients who could benefit from postoperative radiotherapy (PORT) are not well-defined. The study explored the role of PORT on EGFR mutant and wild-type NSCLC patients. We retrospectively searched for resected pIIIA-N2 lung adenocarcinoma patients who underwent EGFR mutation testing. 80 patients with EGFR wild-type and 85 patients with EGFR mutation were included. 62 patients received PORT. In overall population, the median disease-free survival (DFS) was improved in PORT arm compared to non-PORT arm (22.9 vs. 16.1 months; p = 0.036), along with higher 2-year locoregional recurrence-free survival (LRFS) rate (88.3% vs. 69.3%; p = 0.004). In EGFR wild-type patients, PORT was associated with a longer median DFS (23.3 vs. 17.2 months; p = 0.044), and a higher 2-year LRFS rate (86.8% vs. 61.9%; p = 0.012). In EGFR mutant patients, PORT was not significantly correlated with improved survival outcomes. EGFR wild-type may a biomarker to identify the cohort that benefits from PORT.
